These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 36349778)
1. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. Yazıcı D; Yapıcı Eser H; Kıyıcı S; Sancak S; Sezer H; Uygur M; Yumuk V Obes Facts; 2023; 16(2):149-163. PubMed ID: 36349778 [TBL] [Abstract][Full Text] [Related]
2. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047 [TBL] [Abstract][Full Text] [Related]
3. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Barritt AS; Marshman E; Noureddin M Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164 [TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence. Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652 [TBL] [Abstract][Full Text] [Related]
6. JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. Wyne KL; Litwin SE; Cusi K; Guyton JR J Clin Lipidol; 2022; 16(2):115-127. PubMed ID: 35430025 [TBL] [Abstract][Full Text] [Related]
7. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Iepsen EW; Torekov SS; Holst JJ Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877 [TBL] [Abstract][Full Text] [Related]
8. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. Gill L; Mackey S J Womens Health (Larchmt); 2021 Jul; 30(7):1016-1027. PubMed ID: 33626287 [TBL] [Abstract][Full Text] [Related]
9. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197 [TBL] [Abstract][Full Text] [Related]
10. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis. Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115 [TBL] [Abstract][Full Text] [Related]
11. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100 [TBL] [Abstract][Full Text] [Related]
12. GLP-1 physiology informs the pharmacotherapy of obesity. Drucker DJ Mol Metab; 2022 Mar; 57():101351. PubMed ID: 34626851 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. Nolen-Doerr E; Stockman MC; Rizo I Curr Obes Rep; 2019 Sep; 8(3):284-291. PubMed ID: 31124035 [TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect? Li Y; Rosenblit PD Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238 [TBL] [Abstract][Full Text] [Related]
15. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Isaacs D; Prasad-Reddy L; Srivastava SB Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241 [TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Dougherty JA; Guirguis E; Thornby KA Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083 [TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616 [TBL] [Abstract][Full Text] [Related]
18. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. Klen J; Dolžan V Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408810 [TBL] [Abstract][Full Text] [Related]
20. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Iqbal J; Wu HX; Hu N; Zhou YH; Li L; Xiao F; Wang T; Jiang HL; Xu SN; Huang BL; Zhou HD Obes Rev; 2022 Jun; 23(6):e13435. PubMed ID: 35194917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]